A5028310946- Advanced Drug Delivery Systems
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Drug Solubulity and Delivery Systems
- Hepatitis Viruses Studies and Epidemiology
- RNA Interference and Gene Delivery
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- Protein purification and stability
- Hepatitis B Virus Studies
- Nanoparticle-Based Drug Delivery
- Virus-based gene therapy research
- Lipid Membrane Structure and Behavior
- CRISPR and Genetic Engineering
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Electrospun Nanofibers in Biomedical Applications
- Pharmacological Effects and Toxicity Studies
- 3D Printing in Biomedical Research
- Pharmaceutical studies and practices
- Advancements in Transdermal Drug Delivery
- Health Systems, Economic Evaluations, Quality of Life
- Hydrogels: synthesis, properties, applications
University of Nebraska Medical Center
2022-2025
University of Nebraska at Omaha
2022
<title>Abstract</title> Ultra-long-acting (ULA) antiretroviral parenteral formulations, with low injection volumes, high resistance barriers, and short pharmacokinetic (PK) tails, can transform HIV-1 therapeutics. Here, we converted bictegravir (BIC), a potent daily oral drug, into monomeric homodimeric ester prodrugs. The prodrug nanosuspension, NMXBIC, shows sustained plasma BIC levels > 16 times the protein-adjusted 95% inhibitory concentration (PA-IC<sub>95</sub>) for six months after...
Effective antigen delivery facilitates antiviral vaccine success defined by effective immune protective responses against viral exposures. To improve severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) delivery, a controlled biodegradable, stable, biocompatible, and nontoxic polymeric microsphere system was developed for chemically inactivated proteins. SARS-CoV-2 proteins encapsulated in microspheres induced robust immunity. The antigen-loaded can preclude the need repeat...
Long-acting (LA) drug-delivery system (DDS) successes are linked to their abilities harness biocompatible polymers and materials for sustained predictable release of therapeutic agents over an extended period time. For human immune deficiency virus type one (HIV-1) infections, LA DDSs hold great promise in closing the gaps daily oral therapy treatment prevention. Examples Cabenuva, Apretude Sunlenca, which have been shown be safe effective. Alternative promising drug delivery technologies...
Long-acting (LA) drug-delivery system (DDS) successes are linked to their abilities harness biocompatible polymers and materials for sustained predictable release of therapeutic agents over an extended period time. For human immune deficiency virus type one (HIV-1) infections, LA DDSs hold great promise in closing the gaps daily oral therapy treatment prevention. Examples Cabenuva, Apretude Sunlenca, which have been shown be safe effective. Alternative promising drug delivery technologies...
Abstract An extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR establishes a drug depot in monocyte-derived macrophages that extend the drug’s plasma residence time. The LNP’s physicochemical properties improve FTR’s antiretroviral activities, which are linked to ability withstand fluid flow forces and levels of cellular internalization. Each is, measure, dependent on PEGylated composition rate...
Porous polymer microspheres are designed, prepared, and deployed for the co-delivery of biotherapeutics, tissue engineering regenerative medicine. In pharmaceutical science, particle parameters such as porosity dictate characteristics downstream utility by influencing material tuning biodegradation, cargo encapsulation release. However, regulation these parameters, including pore uniformity size, remains challenging. Porogens serve a regulatory method assess how polymer-pore morphology...